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revention Remains Dubious
lthough the primary prevention of atherosclerotic disease events
y the use of statins is both widely promoted and commonly
rescribed, Mills et al. (1) astutely note that the clinical trial
vidence for this clinical practice is inconsistent. There has been a
ack of compelling evidence that statins prevent cardiovascular
vents in initially healthy adults generally, and a near absence of
rial evidence for treatment of hypercholesterolemia in women and
he elderly.
Unfortunately, the meta-analyses and results presented by Mills
t al. (1) can be questioned in several respects. First, although
eclaring exclusion of trials whose subjects included a large
roportion with pre-existing coronary heart disease, the authors do
nclude the entire PROSPER (Pravastatin in Elderly Individuals at
isk of Vascular Disease) sample even though 2,565 participants
44%) had pre-existing heart disease and the trial report provides
esults separately for the primary prevention arm (2). In addition,
he meta-analysis includes 5 trials enrolling only patients with
nown clinical peripheral vascular disease or demonstrable carotid
rtery atherosclerosis. Finally, persons with diabetes are widely
nown to have a substantially higher risk for cardiovascular
vents than nondiabetic persons, yet the meta-analysis includes
large trials of diabetic patients. Trials testing the efficacy of
tatins in diabetic subjects are appropriately summarized else-
here (3) and cannot be used to justify statin treatment in
ondiabetic persons.
Mills et al. (1) could better advance this field by presenting
nalyses that more completely exclude evidence derived from
atients with pre-existing atherosclerosis and diabetes. Further-
ore, we still have no assembled evidence to justify prescribing
tatins to generally healthy women or elderly patients.
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eply
n our systematic review (1) we decided a priori to include trials in
hich 50% of the population had a history of coronary heart
isease. The complete PROSPER (Pravastatin in Elderly Individ-
als at Risk of Vascular Disease) trial fulfills our eligibility criteria
2). Although the PROSPER trial reported the results of their
rimary composite outcome for the primary prevention group, they
id not report the results for the individual components of their
omposite. Thus, this information does not meet our specified end
oint criteria, because we excluded composite outcomes, for good
eason (3).
We believe that there is a continuum of risk among diabetic
atients, and we do not believe that younger, lower-risk patients
hould be considered at the same risk as those patients enrolled
n secondary prevention trials (4). We excluded trials in high-
isk diabetic patients, because we accept that their expected
vent rates are similar to patients with established vascular
isease.
When we exclude the trials with predominantly diabetic pa-
ients and the PROSPER trial, the results of our meta-analyses are
nchanged for both all-cause mortality (relative risk [RR]: 0.93,
5% confidence interval [CI]: 0.87 to 0.99, p  0.039, I2  5.6%,
 0.38) and cardiovascular disease (CVD) mortality (RR:
.84, 95% CI: 0.72 to 0.98, p  0.025, I2  12.3, p  0.31).
herefore, we stand by our conclusions.
This letter gives us the opportunity to update our analysis in
ight of the largest primary prevention trial yet, the JUPITER
Justification for the Use of Statins in Primary Prevention: An
ntervention Trial Evaluating Rosuvastatin) trial of rosuvastatin
or primary cardiovascular prevention (n  17,802) (5). When we
dd this trial to our primary analysis, all-cause mortality is RR:
.92 (95% CI: 0.86 to 0.98, p  0.006, I2  14%, p  0.26) and
VD mortality is RR: 0.85 (95% CI: 0.76 to 0.95, p  0.004,
2  30%, p  0.10).
There is clear evidence for primary and secondary prevention of
linical events across the broad populations involved, including
omen (6). History has displayed how naïve subgroup concerns
an lead to withholding effective treatments from vulnerable
opulations (7).
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